Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0111 | 0.3875 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0068 | 0.1549 | 0.3996 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0073 | 0.1851 | 0.4775 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0092 | 0.2872 | 0.7411 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0111 | 0.3875 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0111 | 0.3875 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0111 | 0.3875 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0111 | 0.3875 | 0.5 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.01 | 0.3288 | 0.7475 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.01 | 0.3288 | 0.7475 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0111 | 0.3875 | 1 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0081 | 0.2266 | 0.5848 |
Entamoeba histolytica | hypothetical protein | 0.0111 | 0.3875 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.01 | 0.3288 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0111 | 0.3875 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0111 | 0.3875 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 70.6 uM | Inhibition of PTP1B | ChEMBL. | 19811915 |
Inhibition (binding) | Inhibition of DPP4 at 100 uM | ChEMBL. | 19811915 | |
Inhibition (binding) | = 16.2 % | Inhibition of alpha-glucosidase at 100 uM | ChEMBL. | 19811915 |
Inhibition (binding) | = 31.67 % | Inhibition of glucose 6 phosphatase assessed as inorganic phosphate release at 100 uM | ChEMBL. | 19811915 |
Inhibition (binding) | = 62.3 % | Inhibition of PTP1B at 100 uM | ChEMBL. | 19811915 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.